FBLG Latest Press Releases

-- June 16, 2026 --

FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers Globe Newswire 8:30 AM

-- June 3, 2026 --

FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers Globe Newswire 7:00 AM

-- May 22, 2026 --

FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting Globe Newswire 8:30 AM

-- May 18, 2026 --

FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics Globe Newswire 8:30 AM

-- May 11, 2026 --

FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus Globe Newswire 8:30 AM

-- May 5, 2026 --

FibroBiologics CEO Issues Letter to Shareholders Globe Newswire 8:30 AM

-- May 4, 2026 --

FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring Globe Newswire 4:01 PM

FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial Globe Newswire 8:30 AM

-- April 30, 2026 --

FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update Globe Newswire 5:55 PM

FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026 Globe Newswire 8:30 AM

-- April 20, 2026 --

FibroBiologics Compliant with All Nasdaq Listing Requirements Globe Newswire 4:01 PM

-- April 10, 2026 --

FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity Globe Newswire 8:30 AM

-- April 2, 2026 --

FibroBiologics Announces Closing of $3 Million Public Offering Globe Newswire 4:01 PM

-- March 31, 2026 --

FibroBiologics Announces Pricing of $3 Million Public Offering Globe Newswire 8:00 PM

FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial Globe Newswire 4:15 PM

-- March 25, 2026 --

FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq's Bid Price Requirement Globe Newswire 4:30 PM

-- March 18, 2026 --

The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven't Noticed Globe Newswire 11:30 AM

-- March 12, 2026 --

FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology Globe Newswire 8:30 AM

-- March 5, 2026 --

FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers Globe Newswire 8:30 AM

-- March 2, 2026 --

FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis Globe Newswire 8:30 AM

-- February 26, 2026 --

FibroBiologics to Present at the BIO Investment & Growth Summit Globe Newswire 8:30 AM

-- February 24, 2026 --

FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update Globe Newswire 4:30 PM

-- February 23, 2026 --

FibroBiologics Granted Extension by Nasdaq to Regain Compliance Globe Newswire 8:30 AM

-- February 10, 2026 --

FibroBiologics' Chairman & CEO Pete O'Heeron Selected to Present at A4LI's H-SPAN Summit at Georgetown University Globe Newswire 8:30 AM

-- February 5, 2026 --

FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia Globe Newswire 8:30 AM

-- January 23, 2026 --

DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event ACCESS Newswire 2:51 PM

-- January 20, 2026 --

FibroBiologics to Present at the DealFlow Discovery Conference Globe Newswire 8:30 AM